Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.71 |
| ▸ | CTSS | P25774 | 1/20 | 0.71 |
| ▸ | CTSK | P43235 | 1/20 | 0.71 |
| ▸ | TACR1 | P25103 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ACE | P12821 | 1/20 | 0.64 |
| ▸ | ECE1 | P42892 | 2/20 | 0.61 |
| ▸ | CCKBR | P32239 | 3/20 | 0.60 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.60 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.58 |
| ▸ | P4HB | P07237 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2727405 | 1.00 | CTSL (0.71) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL2727403 | 1.00 | CTSL (0.71) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL12267036 | 0.92 | CTSL (0.72) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL4849843 | 0.92 | CTSL (0.72) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL15586960 | 0.91 | CTSL (0.68) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL22133112 | 0.91 | CCKBR (0.73) | CTSLCTSSCTSKMAPTTP53 | |
| SCHEMBL1486167 | 0.90 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL29367687 | 0.90 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL30976323 | 0.90 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT | |
| SCHEMBL1003555 | 0.90 | ACE (0.77) | CTSLCTSSCTSKTACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777106-A | Small molecular fluorescent probe based on tryptophan butyrylcholine esterase inhibitor and preparation method and application thereof | 河南大学 | 2024-03-29 | — | — | CN | claimed |
| US-11939398-B2 | Modified peptides for use in treating neurodegenerative disorders | NEURO-BIO LTD (GB) | 2024-03-26 | — | — | US | disclosed |
| CN-109640972-B | Modified peptides for the treatment of neurodegenerative disorders | 神经生物有限公司 | 2023-05-26 | — | — | CN | disclosed |
| EP-3500252-B1 | MODIFIED PEPTIDES FOR USE IN TREATING NEURODEGENERATIVE DISORDERS | NEURO BIO LTD (GB) | 2022-11-02 | — | — | EP | disclosed |
| EP-3407977-B1 | DIAGNOSTIC AND PROGNOSTIC METHODS FOR CANCER AND METASTATIC DISEASE, AND BIOMARKERS FOR THESE CONDITIONS | NEURO BIO LTD (GB) | 2022-10-19 | — | — | EP | disclosed |
| US-11287416-B2 | Cancer | NEURO-BIO LTD (GB) | 2022-03-29 | — | — | US | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| US-5780498-A | PEPTIDE DERIVATIVES FOR CARDIOVASCULAR AND BRAIN DISORDERS | CIBA-GEIGY JAPAN LIMITED (JP) | 1998-07-14 | — | — | US | disclosed |
| WO-1995012611-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | JAPAT LTD. (CH) | 1995-05-11 | — | — | WO | disclosed |
| US-5414013-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5414017-A | Cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0449523-B1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | SQUIBB & SONS INC (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5223516-A | Endopeptidase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0449523-A1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | E.R. SQUIBB & SONS, INC. (US) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11287416-B2 | Cancer | CD44, MKI67, TP53 | CTSL 867/4885CTSS 1138/4885CTSK 650/4885 |
| US-11939398-B2 | Modified peptides for use in treating neurodegenerative disorders | IAPP, NLN, APP | CTSL 644/4885CTSS 879/4885CTSK 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.